The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
Open accessAbstract
Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) received regulatory approvals for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on primary results from the randomized arms of the GO29365 study. After the randomized phase, 106 additional patients received pola + BR in a single-arm extension cohort. We report updated results from the randomized arms and results of the extension cohort. In this phase 1b/2 study, patients with R/R DLBCL who were transplant ineligible received up to six 21-day cycles of pola + BR or BR. The primary end point of the randomized arms was the complete response (CR) rate at end of treatment. Primary objectives of the extension cohort were safety, pharmacokinetic profile, and efficacy of pola + BR. As of 7 July 2020, a total of 192 patients with R/R DLBCL were enrolled in the pola + BR cohort (n = 152 [safety run-in, n = 6; randomized, n = 40; extension cohort, n = 106]) or the BR cohort (n = 40). Significant survival benefit with pola + BR vs BR persisted in the randomized arms (median progression-free survival, 9.2 vs 3.7 months [hazard ratio, 0.39; 95% confidence interval, 0.23-0.66]; median overall survival, 12.4 vs 4.7 months [hazard ratio, 0.42; 95% confidence interval, 0.24-0.72]). In the extension cohort, the independent review committee–assessed objective response rate was 41.5%, and the CR rate was 38.7%; median independent review committee–assessed progression-free survival and overall survival were 6.6 months and 12.5 months, respectively. No new safety signals with pola + BR were identified. Pola + BR is an effective treatment option for patients with R/R DLBCL, with a well-characterized and manageable safety profile. This trial was registered at www.clinicaltrials.gov as #NCT02257567.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ohmachi, K., Niitsu, N., Uchida, T., Kim, S. J., Ando, K., Takahashi, N., Takahashi, N., Uike, N., Eom, H. S., Chae, Y. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5203 · Cited by 171 · cited 1×
“of prior therapies (range) 2 (1-5) 2 (1-7) 2 (1-7) 2 (1-7)”
Cited by
Iacoboni, G., Navarro, V., Martín-López, A. Á., Rejeski, K., Kwon, M., Jalowiec, K. A., Amat, P., Reguera-Ortega, J. L., Gallur, L., Blumenberg, V., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01097 · Cited by 143
De, S. K. (2023) · Medicines for Cancer · doi:10.1016/b978-0-443-13312-1.00009-x · Cited by 1
Metadata
- Authors
- Sehn, L. H., Hertzberg, M., Opat, S., Herrera, A. F., Assouline, S., Flowers, C. R., Kim, T. M., McMillan, A., Ozcan, M., Safar, V., Salles, G., Ku, G., Hirata, J., Chang, Y. M., Musick, L., & Matasar, M. J.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2022-01-19
- Volume
- 6
- Issue
- 2
- Pages
- 533-543
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W3213050308
- Cited by
- 186
- References
- 2
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. https://app.cochat.ai/papers/10.1182/bloodadvances.2021005794
- The paper
- Sehn, L. H., Hertzberg, M., Opat, S., Herrera, A. F., Assouline, S., Flowers, C. R., Kim, T. M., McMillan, A., Ozcan, M., Safar, V., Salles, G., Ku, G., Hirata, J., Chang, Y. M., Musick, L., & Matasar, M. J. (2022). Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Advances. https://doi.org/10.1182/bloodadvances.2021005794
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.